About Uteron Pharma
Uteron Pharma is a company based in Liege (Belgium) founded in 2002 by Jean Michel Foidart and Stijn Van Rompay was acquired by Teva Pharmaceuticals in January 2013. It operates as a B2B. Uteron Pharma has raised $31.09 million across 3 funding rounds from investors including Teva Pharmaceuticals, Nomainvest and Saffelberg Investments. Uteron Pharma operates in a competitive market with competitors including Daré Bioscience, Aspivix, Femasys, Adiana and RemovAid, among others.
- Headquarter Liege, Belgium
- Founders Jean Michel Foidart, Stijn Van Rompay
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$31.09 M (USD)
in 3 rounds
-
Latest Funding Round
$18.68 M (USD), Series B
Mar 28, 2012
-
Investors
Teva Pharmaceuticals
& 5 more
-
Employee Count
Not available
-
Acquired by
Teva Pharmaceuticals
(Jan 23, 2013)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Uteron Pharma
Uteron Pharma has successfully raised a total of $31.09M across 3 strategic funding rounds. The most recent funding activity was a Series B round of $18.68 million completed in March 2012. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Uteron Pharma
Uteron Pharma has secured backing from 6 investors, including venture fund and institutional investors. Prominent investors backing the company include Teva Pharmaceuticals, Nomainvest and Saffelberg Investments.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Locked | Locked | Locked | |
|
Buyouts are pursued by SRIW as a private equity firm.
|
Locked | Locked | Locked | |
|
Noshaq is recognized as a Liège-based investment fund providing financing solutions.
|
Locked | Locked | Locked |
Investor details for Uteron Pharma
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Uteron Pharma
Investment portfolio details for Uteron Pharma
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Uteron Pharma
Detailed financials for Uteron Pharma
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Uteron Pharma Comparisons
Peer comparison for Uteron Pharma
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Uteron Pharma
Uteron Pharma operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Daré Bioscience, Aspivix, Femasys, Adiana and RemovAid, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Non-hormonal pharmaceutical products for female contraceptives are developed.
|
|
| Locked | Locked | Locked |
A next-generation suction-based cervical device for gynecology is provided.
|
|
| Locked | Locked | Locked |
Medical devices for women's healthcare are developed and provided.
|
|
| Locked | Locked | Locked |
Transcervical sterilization systems for permanent birth control are developed.
|
|
| Locked | Locked | Locked |
Medical devices for subdermal implant removal are developed.
|
Detailed competitors of Uteron Pharma
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Uteron Pharma
Complete news archive for Uteron Pharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Uteron Pharma
Uteron Pharma was founded in 2002 and raised its 1st funding round 9 years after it was founded.
Uteron Pharma is headquartered in Liege, Belgium. It is registered at Liege, Liege, Belgium.
Uteron Pharma is a funded company, having raised a total of $31.09M across 3 funding rounds to date.
Uteron Pharma develops products dedicated to female healthcare solutions through providing healthcare solutions, producing pharmaceutical products, womens health, and developing products. Prioritizing client-centric approaches, it ensures high-quality outcomes, innovation, and sustainable practices in its field. It continues to evolve, meeting industry challenges with strategic approaches.
Uteron Pharma's top competitors include Daré Bioscience, Femasys and Aspivix.
Uteron Pharma has 6 investors. Key investors include Teva Pharmaceuticals, Nomainvest, Saffelberg Investments, SRIW, and Noshaq.